Half of all hospitalised children treated with antibiotics for pneumonia did not fulfil radiological, microbiological or laboratory criteria

Acta Paediatr. 2021 Jun;110(6):1924-1931. doi: 10.1111/apa.15808. Epub 2021 Feb 19.

Abstract

Aim: Evaluating the management of paediatric pneumonia is important. We aimed to estimate the proportion of children receiving antibiotics for suspected community-acquired pneumonia (CAP) that were likely to have a bacterial infection. Furthermore, we described antibiotic use in relation to guidelines.

Methods: We conducted a prospective observational study from a paediatric department in Norway. During 2017, all admitted children aged 0-17 years receiving antibiotics for CAP were enrolled in the study. We collected relevant data and defined likely CAP as one or more of the following: radiologically confirmed pneumonia, c-reactive protein of at least 100 mg/L, positive bacterial culture from blood or pleura, detection of bacteria from the nasopharynx associated with atypical pneumonia.

Results: In total, 70 episodes of suspected CAP were included. Median age was 41.5 months, and 36 (51%) were girls. Of all treatments, 38 (54%) fulfilled our criteria for likely CAP. Median duration of treatment was 10 days. Of empirical treatments, 36 (57%) only involved penicillin. None of the children had neutropenia or complications, and only two needed intensive care.

Conclusion: Only half of children receiving antibiotics for suspected CAP were likely to have bacterial infection. Despite no obvious reason, antibiotic treatment was longer than currently recommended.

Keywords: antibiotics; c-reactive protein; community-acquired pneumonia; paediatric pneumonia; radiologically confirmed pneumonia.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Child
  • Child, Hospitalized
  • Child, Preschool
  • Community-Acquired Infections* / diagnostic imaging
  • Community-Acquired Infections* / drug therapy
  • Female
  • Humans
  • Laboratories
  • Male
  • Norway
  • Pneumonia* / diagnostic imaging
  • Pneumonia* / drug therapy

Substances

  • Anti-Bacterial Agents